<VariationArchive VariationID="1459560" VariationName="NC_000020.10:g.(?_43251625)_(43255215_?)del" VariationType="Deletion" Accession="VCV001459560" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1484749" VariationID="1459560">
      <GeneList>
        <Gene Symbol="ADA" FullName="adenosine deaminase" GeneID="100" HGNC_ID="HGNC:186" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>20q13.12</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="44619522" stop="44651699" display_start="44619522" display_stop="44651699" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="43248162" stop="43280375" display_start="43248162" display_stop="43280375" Strand="-" />
          </Location>
          <OMIM>608958</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000020.10:g.(?_43251625)_(43255215_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>20q13.12</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" innerStart="43251625" innerStop="43255215" display_start="43251625" display_stop="43255215" variantLength="3591" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.10" sequenceAccession="NC_000020" sequenceVersion="10" change="g.(?_43251625)_(43255215_?)del" Assembly="GRCh37">
            <Expression>NC_000020.10:g.(?_43251625)_(43255215_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000020.10:g.(?_43251625)_(43255215_?)del AND Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency" Accession="RCV001959061" Version="4">
        <ClassifiedConditionList TraitSetID="495">
          <ClassifiedCondition DB="MedGen" ID="C1863236">Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-02-18" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-02-18" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16199547</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26255240</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26376800</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8227344</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9758612</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="495" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3720" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ADA-SCID</ElementValue>
                <XRef Type="MIM" ID="102700" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SCID DUE TO ADA DEFICIENCY, EARLY-ONSET</ElementValue>
                <XRef Type="MIM" ID="102700" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Adenosine deaminase deficient severe combined immunodeficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Severe combined immunodeficiency due to ADA deficiency</ElementValue>
                <XRef ID="Adenosine+Deaminase+Deficiency/228" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ADA deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Severe combined immunodeficiency due to adenosine deaminase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency</ElementValue>
                <XRef ID="MONDO:0007064" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5748" />
                <XRef ID="5748" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Adenosine deaminase (ADA) deficiency is a systemic purine metabolic disorder that primarily affects lymphocyte development, viability, and function. The clinical phenotypic spectrum includes: Severe combined immunodeficiency disease (SCID), often diagnosed by age six months and usually by age 12 months; Less severe "delayed" onset combined immune deficiency (CID), usually diagnosed between age one and ten years; "Late/adult onset" CID, diagnosed in the second to fourth decades; Benign "partial ADA deficiency" (very low or absent ADA activity in erythrocytes but greater ADA activity in nucleated cells), which is compatible with normal immune function. Infants with typical early-onset ADA-deficient SCID have failure to thrive and opportunistic infections associated with marked depletion of T, B, and NK lymphocytes, and an absence of both humoral and cellular immune function. If immune function is not restored, children with ADA-deficient SCID rarely survive beyond age one to two years. Infections in delayed- and late-onset types (commonly, recurrent otitis, sinusitis, and upper respiratory) may initially be less severe than those in individuals with ADA-deficient SCID; however, by the time of diagnosis these individuals often have chronic pulmonary insufficiency and may have autoimmune phenomena (cytopenias, anti-thyroid antibodies), allergies, and elevated serum concentration of IgE. The longer the disorder goes unrecognized, the more immune function deteriorates and the more likely are chronic sequelae of recurrent infection.</Attribute>
                <XRef ID="NBK1483" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301656</ID>
                <ID Source="BookShelf">NBK1483</ID>
              </Citation>
              <XRef ID="277" DB="Orphanet" />
              <XRef ID="C1863236" DB="MedGen" />
              <XRef ID="MONDO:0007064" DB="MONDO" />
              <XRef Type="MIM" ID="102700" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4264702" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="NM_000022.2_20_Partial deletion (exons 4-7)_43251624_43255215|MedGen:C1863236" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002238785" DateUpdated="2024-06-09" DateCreated="2022-03-28" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-02-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8227344</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26376800</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9758612</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16199547</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26255240</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26376800</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Val177 amino acid residue in ADA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8227344, 26376800, 9758612). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. This variant has not been reported in the literature in individuals with ADA-related conditions. This variant results in the deletion of part of exon 4 and of exon(s) 5-7 (c.244_678+23del) of the ADA gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ADA are known to be pathogenic (PMID: 26255240, 26376800).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ADA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000020.10:g.(?_43251625)_(43255215_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1863236" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4264702" TraitType="Disease" MappingType="XRef" MappingValue="C1863236" MappingRef="MedGen">
        <MedGen CUI="C1863236" Name="Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

